Corinth MedTech, founded in 2014 and based in Cupertino, CA, is dedicated to advancing surgical tools for endoscopic procedures. The company's core mission is to improve patient outcomes through innovative medical technology. Their flagship product is a bipolar transurethral and transcervical resection system designed for the minimally invasive removal of tissue in male patients with benign prostatic hyperplasia (BPH) and female patients with abnormal uterine bleeding (AUB), fibroids, or polyps.
Notable figures associated with Corinth MedTech include experienced medical device professionals and investors focused on healthcare innovation. The company has achieved significant milestones, including regulatory approvals and successful clinical trials, which have validated the efficacy and safety of their resection system. Corinth MedTech's impact lies in providing less invasive surgical options that enhance recovery times and reduce complications for patients suffering from BPH and AUB.